暂停生产！益佰制药被罚暂时停产、 销售小儿止咳糖浆

Core Viewpoint - Guizhou Yibai Pharmaceutical has been ordered to suspend the production and sale of its children's cough syrup due to regulatory non-compliance, which is expected to have a minimal impact on the company's overall performance [1] Group 1: Regulatory Actions - On August 5, Guizhou Yibai Pharmaceutical received a notice from the Guizhou Provincial Drug Administration to immediately suspend the production and sale of its children's cough syrup [1] - The suspension was prompted by findings from the National Medical Products Administration indicating that the company had issues with record-keeping and data reliability [1] Group 2: Financial Impact - The children's cough syrup has contributed a small portion of the company's revenue, with sales figures of 3.42 million yuan, 4.32 million yuan, 8.38 million yuan, and 1.51 million yuan from 2021 to 2024, representing 0.10%, 0.16%, 0.30%, and 0.07% of total revenue respectively [1] - The company stated that the suspension is not expected to significantly affect its financial performance [1] Group 3: Recent Financial Performance - Guizhou Yibai Pharmaceutical projected a net loss of approximately 17.7 million to 21.24 million yuan for the first half of 2025, with a larger loss when excluding non-recurring items [4] - The company reported a 22.92% decline in total revenue for 2024, amounting to 2.174 billion yuan, and a net loss of 317 million yuan, a significant drop of 406.79% year-on-year [4] - The company has faced scrutiny from the Shanghai Stock Exchange due to accounting errors in its financial statements from 2017 to the first quarter of 2024, leading to restatements of prior financial data [5]